Search for a trial

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

This study has been transitioned to CTIS with ID 2023-504761-23-00 check the CTIS register for the current data. The co-primary endpoints of this study are PFS in intermediate and poor-risk subjects, as assessed by an Independent Radiology Review…

The pharmacological effects of using cabozantinib with a light breakfast

The primary is to investigate to the change in exposure to cabozantinib by taking cabozantinib with a light breakfast compared to taking cabozantinib in fasted state. The secondary objectives are to investigate the analytical feasibility of…